Guardant Health, Inc. (GH) Canaccord Genuity’s 46th Annual Growth Conference August 12, 2026 3:00 PM EDT
Company Participants
Helmy Eltoukhy – Co-Founder, Co-CEO & Chairman
AmirAli Talasaz – Co-CEO & Director
Conference Call Participants
Kyle Mikson – Canaccord Genuity Corp., Research Division
Presentation
Kyle Mikson
Canaccord Genuity Corp., Research Division
Welcome to the Canaccord Genuity Growth Conference. I’m Kyle Mikson. I cover Life Science Tools and Diagnostics for Canaccord. Really pleased to welcome you to a fireside chat with Guardant Health, here with us today. Company is a leader in precision oncology diagnostics across screening, MRD and therapy selection.
With us from the company, we have Helmy Eltoukhy, Co-CEO; and AmirAli Talasaz, Co-CEO. Thanks guys for joining us today. Appreciate it.
Helmy Eltoukhy
Co-Founder, Co-CEO & Chairman
Thanks for having us.
Question-and-Answer Session
Kyle Mikson
Canaccord Genuity Corp., Research Division
Let’s start with the 2Q ‘ 26 earnings recap. You guys had earnings recently. Again, like a really strong quarter, nice beat, raised guidance. Can you just walk through the results, puts and takes from the quarter?
Helmy Eltoukhy
Co-Founder, Co-CEO & Chairman
Yes. It’s — once again, I think it shows a business that’s really firing on all cylinders. We have these 3 overlapping S curves, very large market opportunities that are all growing very rapidly. We had great growth with Guardant360 in our oncology business. That’s our flagship therapy selection test. We saw over 30% year-over-year growth there. We saw even greater growth for our tissue test. And it’s really, I think, just the momentum we’re seeing with the Smart platform, this really broad-based genomic — epigenomic platform we launched almost 2 years ago now, and we’re continuing to see sort of that pay dividends in terms of continued volume growth and adoption.
We’re also seeing very good strength
You must be logged in to post a comment Login